Sign In
Buy BLUE
$4.97
+0 (+0%)
At Close: Aug 29, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
02:00pm, Wednesday, 05'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Blue Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Bluebird Bio, Inc. is Fair to Shareholders
08:30am, Wednesday, 05'th Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ:BLUE) to Carlyle Group and SK Capit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
01:40pm, Monday, 03'rd Mar 2025
NEW YORK , March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
10:00am, Saturday, 01'st Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
09:10am, Thursday, 27'th Feb 2025
NEW YORK CITY, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE)Such investors a
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
03:30pm, Monday, 24'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.
03:43pm, Friday, 21'st Feb 2025
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by bluebird bio, Inc. (NASDAQ: BLUE) and its board of directors concerning the proposed ac
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
01:48pm, Friday, 21'st Feb 2025
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell disease
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUE
12:30pm, Friday, 21'st Feb 2025
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securit
PHILADELPHIA, PA / ACCESS Newswire / February 21, 2025 / Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of bluebird bio (NASDAQ:BLUE) regarding the adequacy and fairness
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders
09:02am, Friday, 21'st Feb 2025
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating bluebird (Nasdaq: BLUE) for possible breaches of fiduciary duty and other violations of law in its transaction with Carlyle and SK Capital. Click
BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders
08:52am, Friday, 21'st Feb 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ: BLUE) to Carlyle Group and SK Capital Partners, LP is fair to
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
07:30am, Friday, 21'st Feb 2025
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investm
High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models
09:52am, Tuesday, 18'th Feb 2025
Deshawn "DJ" Chow is one of just over 100 sickle cell patients who have undergone treatment with new gene therapies. CVS Health CEO David Joyner said private insurers and employer-sponsored health pla
